Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06JQS
|
|||
| Former ID |
DIB015208
|
|||
| Drug Name |
HuM195/rGel
|
|||
| Synonyms |
HuM195/rGel, MD Anderson; Conjugated anti-CD33 antibodies (cancer), MD Anderson; HuM195-gelonin immunotoxin (leukemia), Targa Therapeutics; HuM195/rGel (leukemia), Targa Therapeutics; Anti-CD33 immunotoxin (leukemia), Memorial Sloan-Kettering; HuM195-gelonin immunotoxin, Memorial Sloan-Kettering/MD Anderson; HuM195/rGel (intravenous infusion, AML/CML/meylodisplastic syndrome); HuM195/rGel (intravenous infusion, AML/CML/meylodisplastic syndrome), Targa Therapeutics; HuM195/rGel (intravenous infusion, acute myelogenous leukemia/chronic myelogenous leukemia/meylodisplastic syndrome), Targa Therapeutics
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | leukaemia [ICD-11: 2A60-2B33; ICD-9: 208.9] | Phase 1 | [1] | |
| Company |
Targa therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myeloid cell surface antigen CD33 (CD33) | Target Info | . | [2] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007636) | |||
| REF 2 | Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica. 2013 Feb;98(2):217-21. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.